Five Prime Therapeutics, Inc. (FPRX) financial statements (2021 and earlier)

Company profile

Business Address 111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments287156270293422517149
Cash and cash equivalents69564460815015
Short-term investments218101226233414367134
Receivables04513440
Other undisclosed current assets561351472
Total current assets:292167289311440528151
Noncurrent Assets
Operating lease, right-of-use asset2131
Property, plant and equipment11232931654
Restricted cash and investments   22  
Deferred costs     22
Other noncurrent assets5231001
Other undisclosed noncurrent assets222  13(2)
Total noncurrent assets:395733338204
TOTAL ASSETS:332224322344448548156
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1718253724617
Accounts payable0122021
Accrued liabilities111015281562
Employee-related liabilities5777875
Taxes payable     46 
Deferred revenue 1
Debt 4     
Deferred rent credit  1
Deferred revenue and credits14151813
Contract with customer, liability1
Other undisclosed current liabilities5      
Total current liabilities:22232751397920
Noncurrent Liabilities
Long-term debt and lease obligation4246     
Operating lease, liability4246
Liabilities, other than long-term debt252928183251
Deferred revenue and credits28183250
Deferred revenue25
Contract with customer, liability10
Deferred rent credit  18
Other liabilities    000
Total noncurrent liabilities:44512928183251
Total liabilities:677456795711270
Stockholders' equity
Stockholders' equity attributable to parent26515026526539243385
Common stock0000000
Additional paid in capital781582560421397373274
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)0
Retained earnings (accumulated deficit)(516)(432)(295)(156)(5)61(189)
Total stockholders' equity:26515026526539243385
Other undisclosed liabilities and equity     3 
TOTAL LIABILITIES AND EQUITY:332224322344448548156

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net4031380 
Gross profit:1315504031380 
Operating expenses(106)(157)(196)(191)(130)(93)(57)
Other undisclosed operating income      19
Operating income (loss):(93)(142)(146)(151)(99)287(38)
Nonoperating income2563200
Investment income, nonoperating 563200
Other nonoperating income (expense)2  (0) (0)(0)
Income (loss) from continuing operations before income taxes:(91)(137)(140)(149)(97)287(37)
Income tax expense (benefit)7  (2)31(38) 
Net income (loss) available to common stockholders, diluted:(84)(137)(140)(150)(66)250(37)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(84)(137)(140)(150)(66)250(37)
Other comprehensive income (loss)(0)00(0)0(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:(84)(137)(140)(151)(66)250(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: